CIK 0001782223 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Pyxis Oncology, Inc.
Sign in to watch- Ticker
- PYXS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 831160910
- Phone
- (617) 221-9059
- Business address
- 321 HARRISON AVENUE, BOSTON, MA, 02118
- Open-market buys, last 90 days
- $0
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 4 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-09-22 | Dupont Jakob Director | Grant or award · Stock Option (Right to Buy) | +392,461 | 392,461 | ||
| 2023-09-22 | Wadhane Jitendra Chief Accounting Officer | Purchase | +2,500 | $1.74 | $4K | 219,437 |
| 2023-09-22 | Connealy Pamela Ann CFO and COO | Purchase | +5,000 | $1.74 | $9K | 792,106 |
| 2023-09-18 | Sullivan Lara President and CEO | Sale | −8,541 | $2.10 | $18K | 2,403,882 |
| 2023-09-14 | Sullivan Lara President and CEO | Sale | −100 | $2.25 | $225 | 2,412,423 |
| 2023-09-13 | Sullivan Lara President and CEO | Sale | −3,000 | $2.27 | $7K | 2,597,265 |
| 2023-09-13 | Sullivan Lara President and CEO | Shares withheld for taxes | −184,742 | $2.13 | $394K | 2,412,523 |
| 2023-09-12 | Sullivan Lara President and CEO | Sale | −4,917 | $2.25 | $11K | 2,600,265 |
| 2023-09-11 | Sullivan Lara President and CEO | Sale | −20,000 | $2.27 | $45K | 2,605,182 |
| 2023-09-07 | Connealy Pamela Ann CFO and COO | Grant or award | +187,793 | 782,106 | ||
| 2023-09-07 | Wadhane Jitendra Chief Accounting Officer | Grant or award | +93,896 | 211,937 | ||
| 2023-09-07 | Sullivan Lara President and CEO | Grant or award | +469,483 | 2,625,182 | ||
| 2023-08-23 | Dupont Jakob Director | Grant or award · Stock Option (Right to buy) | +5,879 | 5,879 | ||
| 2023-08-23 | Dupont Jakob Director | Grant or award · Stock Option (Right to buy) | +3,534 | 3,534 | ||
| 2023-08-23 | Dupont Jakob Director | Grant or award · Stock Option (Right to buy) | +17,250 | 17,250 | ||
| 2023-03-24 | Sullivan Lara President and CEO | Grant or award | +703,379 | 2,155,699 | ||
| 2023-03-24 | Sullivan Lara President and CEO | Returned to the company · Stock Option (Right to buy) | −990,461 | 0 | ||
| 2023-03-24 | Sullivan Lara President and CEO | Returned to the company · Stock Option (Right to buy) | −61,825 | 0 | ||
| 2023-03-24 | Sullivan Lara President and CEO | Grant or award · Stock Option (Right to buy) | +990,461 | 990,461 | ||
| 2023-03-24 | Sullivan Lara President and CEO | Grant or award · Stock Option (Right to buy) | +61,825 | 61,825 |
Page 4 of 7 · 137 trades